Premium
Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: Report of a case
Author(s) -
Simonart Thierry,
Noel JeanChristophe,
De Dobbeleer Gilbert,
Parent Dominique,
Van Vooren JeanPaul,
De Clercq Erik,
Snoeck Robert
Publication year - 1998
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/(sici)1096-9071(199807)55:3<215::aid-jmv6>3.0.co;2-4
Subject(s) - cidofovir , sarcoma , pathogenesis , kaposi's sarcoma , virology , human herpesvirus , in vivo , in vitro , virus , viral replication , medicine , viral disease , saline , pathology , immunology , biology , cancer research , genetics
The effect of intralesional injections of cidofovir, a nucleotide analog with potent in vitro activity against human herpesvirus 8 (HHV‐8), was studied in vivo in an HIV‐negative patient with classical Kaposi's sarcoma (KS). After five weekly injections of the drug, no clinical, histological, immunohistological, or virological changes could be detected in comparison with saline‐injected lesions. These findings suggest that, once the KS tumor has developed, active viral replication is no longer involved in the pathogenesis of the disease. Alternative hypotheses are that HHV‐8 replication in blood‐borne cells may foster growth of spindle cells in the skin, or that blocking HHV‐8 may not affect existing lesions but may prevent new lesions from developing. J. Med. Virol. 55:215–218, 1998 . © 1998 Wiley‐Liss, Inc.